Scandinavian Real Heart AB (Publ) engages in the design and development of an artificial heart. The company develops Realheart TAH to treat advanced stage heart failure. It also develops RealVAD for pulsating left ventricle assist; PulsePump, a pulsating flow for heart and lung machines; and Sternal Prosthesis for fixing the sternum after open-chest surgery. The company was founded in 1999 and is based in Västerås, Sweden.…
Scandinavian Real Heart (STO: HEART) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 18 employees.
The shares were at 15.20 SEK on 20 November 2026, up 2.0% over 52 weeks. Its 52-week range is 12.95 SEK to 23.70 SEK: the price is 35.9% below the high and 17.4% above the low.
Its market capitalisation is 129.17M SEK.
Scandinavian Real Heart reports return on equity of -56.8% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 36.50M SEK. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.
No upcoming events tracked.